Zymeworks Inc. (NYSE:ZYME) Stock Holdings Decreased by Prosight Management LP

Prosight Management LP lowered its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 820,000 shares of the company's stock after selling 97,599 shares during the period. Zymeworks makes up approximately 3.3% of Prosight Management LP's portfolio, making the stock its 13th biggest holding. Prosight Management LP owned approximately 1.19% of Zymeworks worth $12,005,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Nuveen Asset Management LLC raised its stake in shares of Zymeworks by 0.4% in the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock valued at $3,031,000 after acquiring an additional 886 shares during the period. Deutsche Bank AG raised its stake in shares of Zymeworks by 1.2% in the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after acquiring an additional 17,849 shares during the period. Bridgeway Capital Management LLC raised its stake in shares of Zymeworks by 2.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock valued at $11,121,000 after acquiring an additional 17,092 shares during the period. Blackstone Inc. raised its stake in shares of Zymeworks by 2,171.4% in the 4th quarter. Blackstone Inc. now owns 569,715 shares of the company's stock valued at $8,341,000 after acquiring an additional 544,633 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in shares of Zymeworks in the 4th quarter valued at $108,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Insider Activity at Zymeworks

In related news, Director Ecor1 Capital, Llc purchased 4,397 shares of the company's stock in a transaction on Monday, March 31st. The shares were bought at an average cost of $11.75 per share, for a total transaction of $51,664.75. Following the transaction, the director now owns 17,259,548 shares of the company's stock, valued at $202,799,689. This represents a 0.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders have bought a total of 1,350,347 shares of company stock worth $16,137,499 in the last ninety days. 1.92% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZYME has been the subject of a number of recent analyst reports. HC Wainwright raised their price target on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Lifesci Capital initiated coverage on shares of Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Finally, Citigroup raised their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zymeworks has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

Zymeworks Trading Up 1.6%

NYSE:ZYME traded up $0.18 during mid-day trading on Friday, hitting $11.71. The stock had a trading volume of 332,988 shares, compared to its average volume of 600,155. The stock has a market capitalization of $814.75 million, a price-to-earnings ratio of -7.81 and a beta of 1.24. The company has a 50 day simple moving average of $11.82 and a 200-day simple moving average of $13.39. Zymeworks Inc. has a 52 week low of $8.21 and a 52 week high of $17.70.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $27.11 million for the quarter, compared to the consensus estimate of $20.65 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. Zymeworks's quarterly revenue was up 170.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.42) EPS. As a group, equities research analysts anticipate that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.